On February 2, 2017 AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience reported financial results for the fourth quarter and full-year of 2016 (Press release, AstraZeneca, FEB 2, 2017, View Source [SID1234517638]). Schedule your 30 min Free 1stOncology Demo! Total worldwide product sales for the forth quarter of 2016 was $ 5,260 m USD in comparison to that of $6,207 m USD for the forth quarter of 2015. Total worldwide product sales for the fiscal year ended December 31, 2016 was $21,319 m USD whereas, full year product sales amounted to $23,641 m USD in 2015.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Total oncology product sales increased from $ 2,825 m USD in 2015 to $3,383 m USD in 2016. Total oncology product sales were $930 m USD for the forth quarter of 2016 while total oncology product sales were $716 m USD in the forth quarter of 2015.
Regional sales for 2016 equated to; US – $7,365 m USD, Europe -$5,064 m USD, Established ROW- $3,096 m USD and Emerging markets – $5,794 m USD. Total regional sales of oncology products were; US- $893 m USD, Europe – $733 m USD, Established ROW – $814 m USD and $943 m USD in Emerging Markets.
For AstraZeneca’s detailed sales figures, visit: View Source